In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 476, Issue 1-2, 2001, Pages 83-97

  Albertini, Mark R ^a,d   King, David M ^a   Newton, Michael A ^b   Vacek, Pamela M ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

Human melanoma; Hypoxanthine guanine phosphoribosyltransferase deficient lymphocytes; Immune activation; Somatic mutation; T cells

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CELL ACTIVATION; CELL MUTANT; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENDER; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPH NODE; LYMPHOMA; MALE; MELANOMA; MUTATION RATE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR GENE; REGRESSION ANALYSIS; T LYMPHOCYTE;

ADULT; AGED; CASE-CONTROL STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; MUTATION; T-LYMPHOCYTES; THIOGUANINE;

EID: 0035832360     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(01)00084-7     Document Type: Article

References (50)

1. Production of stable cytolytic T-cell clones directed against autologous human melanoma
2. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas
3. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition
4. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T-lymphocytes
5. Teaching the immune system to fight cancer
6. A gene encoding an antigen recognized by cytolotic T-lymphocytes on a human melanoma
7. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
8. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas
9. Identification of melanoma antigens recognized by T-lymphocytes and their use in the immunotherapy of cancer
10. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
11. Induction of anti-tumor cytotoxic T-lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
12. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides
13. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression
14. Antigen-specific agents in development
15. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
16. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
17. Analysis of T-cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma: Evidence for in situ T-cell clonal expansion
18. Direct evidence to support the immunosurveillance concept in a human regressive melanoma
19. Predominant expression of T-cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma
20. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
21. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
22. Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resitant mutant frequency in humans
23. The hprt- mutant T-cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis
24. Assessment of in vivo frequency of mutated T-cells in patients with systemic lupus erythematosus
25. T-cells responsive to myelin basic protein in patients with multiple sclerosis
26. Frequency of hypoxanthine guanine phosphoribosyltransferase (hprt-) T-cells in the peripheral blood of cardiac transplant recipients: A non-invasive technique for the diagnosis of allograft rejection
27. Analysis of T-cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients
28. A human T-cell specific DNA clone encodes a protein having extensive homology to immunoglobin chains
29. Rearrangement of two distinct T-cell gamma-chain variable-region genes in human DNA
30. Mathematical statistics: Basic ideas and selected topics
31. Measurement of hprt mutant frequencies in T-lymphocytes from healthy human populations
32. Thioguanine-resistant mutant frequency in T-lymphocytes from a healthy human population
33. Use of the clonal assay for the measurement of frequencies of hprt mutants in T-lymphocytes from five control populations
34. Possible association between mutant frequency in peripheral lymphocytes and domestic radon concentrations
35. A study of the effects of exposure on cleanup workers at the Chernobyl nuclear reactor accident using multiple end end points
36. Gene mutations with characteristic deletions in cord blood T-lymphocytes associated with passive maternal exposure to tobacco smoke
37. Factors influencing mutation at the hprt locus in T-lymphocytes: Women treated for breast cancer
38. Increased mutation frequency following treatment with cancer chemotherapy
39. Frequencies of hprt mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: A prospective study
40. Emergence of genetic instability in children treated for leukemia
41. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy
42. Methyl DNA adducts, DNA repair, and hypoxanthine guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea
43. Molecular analyses of in vivo hprt mutations in human T-lymphocytes. I. Studies of low frequency 'spontaneous' mutants by Southern blots
44. Evaluation of mutant frequencies at the hprt and the T-cell receptor loci in pediatric cancer patients before treatment
45. Mutant frequency at the hprt locus in human lymphocytes in a case-control study of lung cancer
46. The hprt mutant frequency and aromatic DNA adduct level in non-smoking and smoking lung cancer patients and population controls
47. Deletion mutations in the hprt gene of T-lymphocytes as a biomarker for genomic rearrangements important in human cancers
48. In vivo human somatic mutation: Frequency and spectrum with age